Ignite Creation Date:
2024-05-05 @ 4:39 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00283478
Status:
COMPLETED
Last Update Posted:
2007-10-31
First Post:
2006-01-26
Brief Title:
Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer
Sponsor:
Kentuckiana Cancer Institute
Organization:
Kentuckiana Cancer Institute
Study Overview
Official Title:
Randomized Pilot Study of Supplemental Iscar in Combination With Gemcitabine vs Gemcitabine Alone as Second Line Treatment for Advanced Non-Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2007-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine if Iscar Quercus improves immune function and quality of life among patients with stage IV non-small cell lung cancer
Detailed Description:
RAndomized pilot study of supplemental Iscar in combination with Gemcitabine vs Gemcitabine alone as second line treatment for advanced non-small cell lung cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Mistletoe | None | None | None |